-

RapidAI to Enter ISC 2024 Showcasing Extensive Research and Unparalleled Industry Leadership

Data-heavy presence at the International Stroke Conference validates RapidAI as the clear choice in clinical AI for stroke care

SAN MATEO, Calif.--(BUSINESS WIRE)--RapidAI, the global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, will showcase its clinical expertise and industry-leading innovation at the American Heart Association’s International Stroke Conference (ISC) in Phoenix, AZ, February 7-9. Through various research presentations, poster abstracts, and learning sessions, RapidAI will highlight how its AI platform is reshaping the industry and driving confident, efficient, and accessible patient care.

“Our commitment to research and finding new, improved ways to enhance patient outcomes is a core pillar for us,” said Dr. David Stoffel, chief business officer of RapidAI. “Our dedication to enabling clinical excellence in stroke care has never been stronger, and the data that will be unveiled at ISC serves as yet another proof point in how we continuously push the envelope to expand access to better stroke care.”

RapidAI-Related Live Sessions and Events at ISC:

February 7, 2024

  • Learning Studio: The Practical Use of AI in Building a Stroke Program, Gregory Albers, M.D., and Vivek Yedavalli, M.D., M.S.
    • February 7, 12:45 - 1:15 PM MST at Learning Studio 1
  • Satellite Symposium: The Frontier of Stroke Diagnosis (RapidAI): How Can Artificial Intelligence Improve Acute Stroke Care for Ischemic and Hemorrhagic Stroke?, Gregory Albers, M.D., as a part of EMCREG-International’s Satellite Symposium, ‘Optimizing Critical Care for Intracranial Hemorrhage: Impact of Anticoagulation Reversal, Care Building, and Artificial Intelligence on Outcome’
    • February 7, 6:00 - 7:30 PM MST at Hyatt Regency Phoenix, Phoenix Ballroom, 2nd Floor
  • Poster Presentation: Detecting MeVOs and Collateral Assessment with Multimodality AI Approach, Mahdi Sowlat, M.D.
    • February 7, 6:25 - 6:30 PM MST at Poster Hall, Halls 5-6

February 8, 2024

  • Late-Breaking Science Oral Abstracts IV: Subgroup Analyses From the TIMELESS Trial, Gregory Albers, M.D.
    • February 8, 4:06 - 4:18 PM MST at North 121 A-C
  • Poster Presentation: Acute Ischemic Stroke Patients After Implementation of the RapidAI Platform in a Comprehensive Stroke Center in Santiago, Chile, Pablo Lavados, M.D., presented by Greg Albers, M.D.
    • February 8, 6:00 - 7:00 PM MST at Poster Hall, Halls 5-6
  • Presentation and Networking Event: AI Beyond the Algorithm, Dan Gibson, M.D.
    • February 8, 6:00 - 8:00 PM MST at the Croft Downtown
    • RapidAI-hosted event with clinical insights, networking opportunities, and live demo stations

For more about RapidAI’s ISC presence, including presentations and 11 posters being showcased, please visit us at ISC Booth #805 or find the full schedule of sessions and more here.

About RapidAI

RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Leading the next evolution of clinical decision-making and patient workflow, RapidAI is empowering physicians to make faster decisions for better patient outcomes. Based on intelligence gained from 12 million scans in more than 2,200 hospitals in over 100 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI – where AI meets patient care.

Contacts

RapidAI Media Contact:
Jessica Stebing
Group Manager, Marketing Communications
260.336.6202
stebing@ischemaview.com

RapidAI


Release Versions

Contacts

RapidAI Media Contact:
Jessica Stebing
Group Manager, Marketing Communications
260.336.6202
stebing@ischemaview.com

More News From RapidAI

RapidAI and AWS Strengthen Relationship: Accelerate Global Deployment of Deep Clinical AI

CHICAGO--(BUSINESS WIRE)--RapidAI, the pioneer of deep clinical AI and global leader in enterprise imaging, and Amazon Web Services (AWS), today announced a strengthened working relationship to accelerate the global adoption and scalability of deep clinical AI in healthcare. The companies will focus on co-development and go-to-market alignment, bringing together AWS’s AI infrastructure and machine learning pipelines with RapidAI’s deep clinical expertise and multimodal healthcare data. At RSNA...

RapidAI Extends the Reach of Deep Clinical AI with Five New FDA Clearances

SAN MATEO, Calif.--(BUSINESS WIRE)--New clearances expand the Rapid Enterprise Platform, advancing radiology precision, and elevating neurology and vascular care through deep clinical AI...

RapidAI Earns FDA Clearance for Rapid Aortic, Bringing AI-Driven Aortic Measurements and Surveillance to Care Teams

SAN MATEO, Calif.--(BUSINESS WIRE)--RapidAI, the pioneer of deep clinical AI and global leader in enterprise imaging, today announced U.S. Food and Drug Administration (FDA) clearance of Aortic Management, part of the Rapid Aortic product, a comprehensive deep clinical AI solution designed to transform the acute assessment and longitudinal management of aortic disease. RapidAI remains committed to advancing deep clinical AI—intelligent algorithms that go far beyond traditional triage to meaning...
Back to Newsroom